Draper and Pfizer partner on human organ-on-a-chip technology
The companies will collaborate to create unique versions of Draper’s Microphysiological Systems (MPS) technology, with the aim of creating more effective disease models...
List view / Grid view
The companies will collaborate to create unique versions of Draper’s Microphysiological Systems (MPS) technology, with the aim of creating more effective disease models...
26 May 2016 | By Victoria White, Digital Content Producer
Scientists have found that a widely prescribed painkiller, celecoxib, slows the growth rate of a specific kind of cancer in animal models...
11 May 2016 | By Victoria White, Digital Content Producer
Pfizer has awarded a total of more than $1 million in funding to five leading advocacy organisations to support metastatic breast cancer scientific research...
6 April 2016 | By Victoria White
The decision was driven by the actions announced by the US Department of Treasury to reform inversion tax rules, which the companies concluded qualified as an “Adverse Tax Law Change”. Market rumour suggests that Pfizer will now target Shire or AstraZeneca and shares in both companies went up with the…
22 March 2016 | By Victoria White
The Human Vaccines Project is focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection...
9 February 2016 | By Victoria White
The programme aims to bring together breast cancer researchers and pharmaceutical companies to pool resources and stop women dying from breast cancer by 2050...
29 January 2016 | By SMi Group
SMi group reports: Doug Johnson, Research Fellow at Pfizer will be giving a keynote address on Day 1 at the SMi’s 15th annual Advances and Progress in Drug Design conference...
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
14 January 2016 | By Victoria White
Calibr's antibody fusion technology provides a proprietary, modular approach to developing long-acting biotherapeutics based on peptide and protein agonists and antagonists...
12 January 2016 | By Victoria White
The first four investments of the newly focused initiative include $46 million in financing to companies at early stages of the discovery process that are actively exploring Conditionally Active Biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy...
8 December 2015 | By Victoria White
BioAtla and Pfizer will each have a license to the other's respective technology to pursue the development and commercialisation of several CAB-ADC antibodies...
30 November 2015 | By Victoria White
Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...
8 September 2015 | By Victoria White
AMRA will collaborate with Pfizer to help provide a better understanding of the relationship between body composition and risk for obesity related diseases...
18 August 2015 | By The European Antibody Congress
The European Antibody Congress takes place 9-11 November 2015 at the Congress Centre, Basel...
8 July 2015 | By Victoria White
Pfizer’s Centres for Therapeutic Innovation and the Jeffrey Modell Foundation are to collaborate to conduct research in the field of immunological diseases...